This also provides an additional explanation by which low-intensity inflammation that is suitable for CHF may contribute to development of endothelial dysfunction and might reflect a risk of unfavorable clinical outcomes irrespective of traditional biomarkers, such as NT-pro-BNP, NYHA class, and LVEF. This evidence concerns the gene NPPB and endothelial dysfunction.